The FDA approved nipocalimab (Imaavy) injection to treat adults and children ages 12 and older with generalized myasthenia ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the treatment of generalized myasthenia gravis.

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that teems with competition, both approved and ...

The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Highlights in myasthenia gravis from AAN 2025 include trials of new therapy inebilizumab, new data on the approved rozanolixizumab for ocular symptoms, and insights into current clinical practice.

MuSK antibody positive adults and pediatric gMG patients aged 12 and older. FDA Approves New Treatment for Generalized ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

The US FDA has approved Johnson & Johnson's drug to treat patients aged 12 years and older with an immune-mediated disorder ...